AstraZeneca: A Rare Compound Growth Opportunity In Biopharma (AZN)

分组1 - AstraZeneca PLC (AZN) aims to become the first biopharma company to overcome cyclicality through optimizing its commercial and pipeline asset base [1] - The company is leveraging its experience and economies of scale to enhance its operational efficiency [1]